Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 669
Filter
1.
Naunyn Schmiedebergs Arch Pharmacol ; 397(4): 2389-2400, 2024 04.
Article in English | MEDLINE | ID: mdl-37837474

ABSTRACT

BACKGROUND: 7,12-Dimethylbenzanthracene (DMBA) is a member of the polycyclic aromatic hydrocarbon family. It is a member of the polycyclic aromatic hydrocarbon family. It is a mutagenic, carcinogenic, and immunosuppressor agent. Cannabidiol (CBD) is a phytocannabinoid. It has anticonvulsant, anti-inflammatory, anti-anxiety, antioxidant, and anti-cancer properties. The purpose of this study was to investigate the possible protective and therapeutic benefits of CBD oil in DMBA-induced leukemia in rats. METHOD: Experimental animals were divided into six groups of five rats each. Group 1 (normal control) included healthy rats. Group 2 included normal rats that received olive oil. Group 3 included normal rats that received CBD. Group 4 included the DMBA-induced leukemic group. Group 5 (prophylactic group) included rats that received CBD as a prophylaxis before IV injection with DMBA. Group 6 (treated group) included DMBA-induced leukemic rats that received CBD as treatment. Liver functions (total, direct and indirect bilirubin, alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST), albumin, globulin, and albumin globulin ratio) were measured. Superoxide dismutase (SOD) and catalase (CAT) were also measured. Total RNA extraction followed by-real time qRT-PCR gene expression of LC3-II, Beclin, mTOR, and P62 was performed. Histopathological examination of liver and spleen tissues was performed. RESULTS: Administration of CBD in groups 5 and 6 resulted in a significant improvement of the levels of liver functions compared to the leukemic untreated rats. Also, the levels of catalase and SOD significantly increased after treatment with CBD compared to the leukemic group. After treatment with CBD in groups 5 and 6, there were downregulations in the expression of all studied genes compared to leukemic untreated rats. Treatment with CBD was more statistically effective than prophylactic use. CONCLUSION: Administration of CBD resulted in a significant improvement in the biochemical, antioxidant status, morphological, and molecular measures in DMBA-induced leukemia in adult male rats. The therapeutic use was more effective than the prophylactic one.


Subject(s)
Cannabidiol , Globulins , Leukemia, Experimental , Rats , Male , Animals , Antioxidants/pharmacology , Catalase/metabolism , 9,10-Dimethyl-1,2-benzanthracene/metabolism , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Leukemia, Experimental/drug therapy , Leukemia, Experimental/metabolism , Leukemia, Experimental/pathology , Liver , Globulins/metabolism , Globulins/pharmacology , Superoxide Dismutase/metabolism , Albumins/metabolism
2.
J Surg Res ; 282: 137-146, 2023 02.
Article in English | MEDLINE | ID: mdl-36274448

ABSTRACT

INTRODUCTION: Anal dysplasia and anal cancer are major health problems. This study seeks to determine if inhibition of mTOR and/or PI3K pathways is effective at anal cancer prevention in mice with/without established precancerous lesions of the anus (anal dysplasia). METHODS: K14E6/E7 mice were entered into the study at 5 wk, 15 wk, or 25 wk of age. Mice were treated with a topical carcinogen, 7,12-Dimethylbenz[a]anthracene (DMBA), which ensures carcinoma development within 20 wk. Treatment groups included: no treatment, DMBA only, topical Pictilisib (PI3K inhibitor) with/without DMBA, topical Sapanisertib (mTOR inhibitor) with/without DMBA, and topical Samotolisib (dual PI3K/mTOR inhibitor) with/without DMBA. Mice underwent weekly observations for anal tumor development (tumor-free survival). After 20 wk of treatment, anal tissue was harvested and evaluated histologically for squamous cell carcinoma (SqCC). RESULTS: All topical treatments in conjunction with DMBA increased tumor-free survival in mice that started treatment at 15 wk of age when compared to DMBA-only treatment, except for Pictilisib + DMBA in males. Topical Sapanisertib increased tumor-free survival in mice regardless of starting treatment age. When examining tissue for microscopic evidence of SqCC, only topical Samotolisib in males decreased SqCC in the 15 wk starting mice. CONCLUSIONS: Sapanisertib, the mTOR inhibitor, had the greatest effect, in terms of increasing tumor-free survival, regardless of starting time point or sex. Unlike the other treatments, Samotolisib, the dual PI3K/mTOR inhibitor, decreased microscopic evidence of SqCC when starting treatment at 15 wk of age but only in male mice.


Subject(s)
Anus Neoplasms , Carcinoma, Squamous Cell , Mice , Male , Animals , Phosphatidylinositol 3-Kinases , MTOR Inhibitors , Anal Canal/pathology , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Anus Neoplasms/prevention & control , Anus Neoplasms/pathology , TOR Serine-Threonine Kinases/metabolism , Carcinoma, Squamous Cell/pathology
3.
Cells ; 11(8)2022 04 12.
Article in English | MEDLINE | ID: mdl-35455979

ABSTRACT

Polyphenols are capable of decreasing cancer risk. We examined the chemopreventive effects of a green tea (Camellia sinensis) extract, polyphenol extract (a mixture of blackberry (Rubus fruticosus), blackcurrants (Ribes nigrum), and added resveratrol phytoalexin), Chinese bayberry (Myrica rubra) extract, and a coffee (Coffea arabica) extract on 7,12-dimethylbenz[a]anthracene (DMBA) carcinogen-increased miR-134, miR-132, miR-124-1, miR-9-3, and mTOR gene expressions in the liver, spleen, and kidneys of CBA/Ca mice. The elevation was quenched significantly in the organs, except for miR-132 in the liver of the Chinese bayberry extract-consuming group, and miR-132 in the kidneys of the polyphenol-fed group. In the coffee extract-consuming group, only miR-9-3 and mTOR decreased significantly in the liver; also, miR-134 decreased significantly in the spleen, and, additionally, miR-124-1 decreased significantly in the kidney. Our results are supported by literature data, particularly the DMBA generated ROS-induced inflammatory and proliferative signal transducers, such as TNF, IL1, IL6, and NF-κB; as well as oncogenes, namely RAS and MYC. The examined chemopreventive agents, besides the obvious antioxidant and anti-inflammatory effects, mainly blocked the mentioned DMBA-activated factors and the mitogen-activated protein kinase (MAPK) as well, and, at the same time, induced PTEN as well as SIRT tumor suppressor genes.


Subject(s)
Anticarcinogenic Agents , MicroRNAs , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Anticarcinogenic Agents/pharmacology , Biomarkers , Coffee , Gene Expression , Mice , Mice, Inbred CBA , MicroRNAs/genetics , Polyphenols/pharmacology , Polyphenols/therapeutic use , TOR Serine-Threonine Kinases/genetics
4.
Biomed Pharmacother ; 147: 112666, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35124384

ABSTRACT

Naturally occurring phytochemicals especially polyphenolic compounds have received increasing attention as chemopreventive agents. The chemopreventive potential of the ethanolic extract of Salvadora persica L. fruits SP, (the arak tree or miswak) on 7,12-dimethylbenz (a) anthracene (DMBA)-induced mammary carcinogenesis in female albino rats was investigated in this work. Ethanolic extract of SP fruits was supplemented to the experimental groups at a concentration of 500 mg/kg body weight for 22 weeks. Administration of SP extract suppressed DMBA-induced mammary carcinogenesis as revealed by incidence of tumors in histological investigation. There was a significant reduction in cell proliferation and an increase in apoptosis with downregulation of estrogen receptor expression in the mammary tissue of SP-treated animals. Additionally, SP extract prevented the oxidative damage induced in breast tissues of DMBA-treated rats. SP treatment also decreased the viability of MCF-7 breast cancer cells and induced early and late apoptosis and induced S cell cycle arrest. The chemo-preventive properties and anticancer effects of SP could be attributed to its anti-oxidative and a high percentage of phenolic compounds and esters which were detected here in the SP fruit extract.


Subject(s)
Mammary Neoplasms, Experimental/drug therapy , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Receptors, Estrogen/drug effects , Salvadoraceae , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Apoptosis/drug effects , Cell Proliferation/drug effects , Down-Regulation/drug effects , Female , Humans , MCF-7 Cells , Random Allocation , Rats , Rats, Wistar , Xenograft Model Antitumor Assays
5.
Invest New Drugs ; 39(6): 1484-1492, 2021 12.
Article in English | MEDLINE | ID: mdl-34031785

ABSTRACT

Pancreatic cancer is among the most refractory malignancies with poor prognosis. Thus, preventive approaches, in addition to the development of novel therapeutic strategies are essential for this type of cancer. KRAS mutations occur very early in the development of pancreatic cancers and could be targeted for its prevention, yet specific inhibitors for mutated KRAS are lacking. Accordingly, Glutathione-S Transferase p1 (GSTP1), which we recently found to be an autocrine stimulator of mutated KRAS signaling, is predicted to be an alternative target for chemoprevention of pancreatic cancer. In this study, chemopreventive effects of O-Hexadecyl-γ-glutamyl-S-benzyl-cysteinyl-D-phenyl glycine-Ethylester (HGBPE), which we previously synthesized to inhibit GSTP1 activity, was analyzed for its effect on the prevention of a rat pancreatic carcinogenesis model induced by 7,12-dimethyl-benzanthracene (DMBA). Rats administered with DMBA were grouped into five cohorts. In the treated group I, which was treated neither with HGBPE nor vehicle, sequential appearance of precancerous lesions, ductal complexes, and adenocarcinoma was confirmed as previously reported. We also confirmed in this group that mutations of KRAS and expression of GSTP1 simultaneously occurred in the ductal complex. To rats of groups II and IV, HGBPE was administered, and vehicle to those of group III and V. In groups of II and IV, the incidence of both ductal complex and adenocarcinoma were significantly lower than those in groups III and V. These data clearly suggest the efficacy of HGBP as a potential chemopreventive agent for pancreatic cancer.


Subject(s)
Glutathione S-Transferase pi/pharmacology , Pancreatic Neoplasms/prevention & control , Proto-Oncogene Proteins p21(ras)/drug effects , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Disease Models, Animal , Pancreatic Neoplasms/chemically induced , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects
6.
PLoS One ; 16(2): e0246022, 2021.
Article in English | MEDLINE | ID: mdl-33539381

ABSTRACT

Both the intake of beneficial olive oil and of harmful trans-fatty acids (TFAs) in consumed foods are of great significance in tumor biology. In our present study we examined the effects they exert on the expression patterns of miR-134, miR-132, miR-124-1, miR-9-3 and mTOR in the liver, spleen and kidney of mice treated with 7,12-dimethylbenz [a] anthracene (DMBA). Feeding of TFA-containing diet significantly increased the expression of all studied miRs and mTORC1 in all organs examined, except the expression of mTORC1 in the spleen and kidney. Diet containing olive oil significantly reduced the expression of miR-124-1, miR-9-3 and mTORC1 in the liver and spleen. In the kidney, apart from the mTORC1 gene, the expression of all miRs examined significantly decreased compared to the DMBA control. According to our results, the cell membrane protective, antioxidant, and anti-inflammatory effects of olive oil and the cell membrane damaging, inflammatory, and carcinogenic properties of TFA suggest negative feedback regulatory mechanisms. In contrast to our expectations, mTORC1 gene expression in the kidney has not been shown to be an appropriate biomarker-presumably, because the many complex effects that regulate mTOR expression may quench each other.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene/pharmacology , Gene Expression Regulation/drug effects , Mechanistic Target of Rapamycin Complex 1/genetics , MicroRNAs/genetics , Olive Oil/pharmacology , Trans Fatty Acids/pharmacology , Animals , Female , Mice
7.
Geroscience ; 41(2): 209-227, 2019 04.
Article in English | MEDLINE | ID: mdl-31037472

ABSTRACT

There is significant overlap between the cellular and molecular mechanisms of aging and pathways contributing to carcinogenesis, including the role of genome maintenance pathways. In the field of geroscience analysis of novel genetic mouse models with either a shortened, or an extended, lifespan provides a unique opportunity to evaluate the synergistic roles of longevity assurance pathways in cancer resistance and regulation of lifespan and to develop novel targets for interventions that both delay aging and prevent carcinogenesis. There is a growing need for robust assays to assess the susceptibility of cancer in these models. The present review focuses on a well-characterized method frequently used in cancer research, which can be adapted to study resilience to genotoxic stress and susceptibility to genotoxic stress-induced carcinogenesis in geroscience research namely, chemical carcinogenesis induced by treatment with 7,12-dimethylbenz(a)anthracene (DMBA). Recent progress in understanding how longer-living mice may achieve resistance to chemical carcinogenesis and how these pathways are modulated by anti-aging interventions is reviewed. Strain-specific differences in sensitivity to DMBA-induced carcinogenesis are also explored and contrasted with mouse lifespan. The clinical relevance of inhibition of DMBA-induced carcinogenesis for the pathogenesis of mammary adenocarcinomas in older human subjects is discussed. Finally, the potential role of insulin-like growth factor-1 (IGF-1) in the regulation of pathways responsible for cellular resilience to DMBA-induced mutagenesis is discussed.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene/pharmacology , Aging/genetics , DNA Damage , Mammary Neoplasms, Experimental/chemically induced , Animals , Carcinogenesis/genetics , Disease Models, Animal , Female , Geriatrics , Humans , Longevity/genetics , Male , Mammary Neoplasms, Experimental/genetics , Mice , Rats, Sprague-Dawley , Research , Rodentia
8.
Exp Anim ; 68(3): 257-265, 2019 Aug 14.
Article in English | MEDLINE | ID: mdl-30760660

ABSTRACT

Serous borderline ovarian tumors (SBOTs) behave between benign cystadenomas and carcinomas, and the effective detection and clinical management of SBOTs remain clinical challenges. Because it is difficult to isolate and enrich borderline tumor cells, a borderline animal model is in need. 7,12-dimethylbenz[a]anthracene (DMBA) is capable of inducing the initiation, promotion, and progression of serous ovarian tumors. This study aims to investigate the proper dosage and induction time of DMBA for rat models of SBOTs, and explore their morphological features demonstrated by magnetic resonance (MR) imaging and molecular genetic characteristics. Rats were randomly divided into six groups (1 mg/70 D, 2 mg/70 D, 3 mg/70 D, 2 mg/50 D, 2 mg/90 D, and 2 mg/110 D). The 3 mg/70 D group induced the most SBOTs (50.0%, 12/24). The micropapillary projections were shown on MR imaging, which was the characteristic of SBOTs. The Cyclin D1 characterizing an early pathogenetic event strongly expressed in induced serous benign tumors (SBTs). The immunoreactivity staining scores of P53 expression significantly increased from SBTs, SBOTs to serous ovarian carcinomas (SCAs), which elucidate that P53 might be a promising biomarker to grade serous ovarian tumors. Based on morphological and molecular genetic similarities, this rodent SBOT model was suitable for investigating the pathogenesis of serous ovarian tumors and developing an early detection strategy.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene/pharmacology , Carcinogens/pharmacology , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Rats , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Ovarian Neoplasms/chemically induced , Random Allocation , Rats, Sprague-Dawley , Time Factors
9.
Biol Pharm Bull ; 42(4): 580-585, 2019 Apr 01.
Article in English | MEDLINE | ID: mdl-30674757

ABSTRACT

Chinese tree shrew, an animal exhibited closer evolutionary relationship with humans compared to rodents, is getting increasingly attentions as an appealing experimental animal model for human diseases. However, a high-efficiency and stable method to establish tree shrew breast precancerous lesions model has not been clearly elucidated. Thus, the current study aimed to explore the way of establishing breast precancerous model in tree shrew and investigate the pathologic characteristics of induced breast precancerous lesions. The results indicated that 7,12-dimethylbenz(a)anthracene (DMBA) could induce breast lesions in tree shrews. However, comparing to DMBA alone, an addition of medroxyprogesterone acetate (MPA) to DMBA critically increased the rate of induced breast lesion in tree shrews. Half of induced breast lesions were intraductal papilloma and the others were atypical ductal hyperplasia. Induced lesions showed positive expression of estrogen receptor α (ERα), progesterone receptor (PR) and cytokeratin 5/6 (CK5/6), but negative expression of human epidermal growth factor receptor-2 (Her-2). The expression of B cell lymphoma-extra large (Bcl-xl) was significantly higher and the expression of B cell lymphoma 2 associated X protein (Bax) was significantly lower in the precancerous lesions (atypical ductal hyperplasia) compared to benign tumor (intraductal papilloma). These results suggest that DMBA is able to induce breast lesions in tree shrews. Combination of DMBA and MPA may be more effective to establish breast precancerous lesion tree shrew models. Tree shrew might be a promising animal model for studying the tumorogenesis of breast cancer.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene/pharmacology , Mammary Neoplasms, Experimental/chemically induced , Medroxyprogesterone Acetate/pharmacology , Precancerous Conditions/chemically induced , Tupaiidae , Animals , Drug Synergism , Estrogen Receptor alpha/metabolism , Female , Keratin-5/metabolism , Keratin-6/metabolism , Mammary Neoplasms, Experimental/metabolism , Mammary Neoplasms, Experimental/pathology , Precancerous Conditions/metabolism , Receptor, ErbB-2/metabolism , Receptors, Progesterone/metabolism
10.
Biomed Res Int ; 2018: 2024602, 2018.
Article in English | MEDLINE | ID: mdl-29770327

ABSTRACT

The present study was designed to evaluate the in vitro and in vivo antitumor effects of A. seyal hydroethanolic extract on breast cancer. The cytotoxicity of A. seyal extract was evaluated using resazurin reduction assay in 9 cell lines. Further, the protective effect of the hydroethanolic extract of A. seyal stem barks was evaluated on 7,12-dimethylbenz(a)anthracene- (DMBA-) induced breast cancer rat model. Incidence, burden, volume, and histological analysis of mammary tumors were measured. The Acacia seyal extract exhibited CC50 of 100 in MCF-7 cells after 24 h. In vivo, no tumors were detected in rats from the control group, while 11 rats out of 12 (91.66%) developed mammary tumors in the DMBA-exposed group receiving only the vehicle. Acacia seyal extract significantly (p < 0.01) and in the dose-dependent manner reduced tumor incidence (3 rats out of 12 at the dose of 300 mg/kg), burden [62.1% (150 mg/kg) and 65.8% (300 mg/kg)], and mass. It protected rats against DMBA-induced breast hyperplasia, with an optimal effect at the dose of 300 mg/kg. Taken altogether, these results suggest that the hydroethanolic extract of Acacia seyal might contain phytoconstituents endowed with antitumoral properties, which could protect against the breast cancer induced in rats.


Subject(s)
Acacia/chemistry , Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Cytotoxins/pharmacology , Fabaceae/chemistry , Mammary Neoplasms, Experimental/drug therapy , Plant Extracts/pharmacology , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Breast Neoplasms/chemically induced , Carcinogens/pharmacology , Cell Line , Cell Line, Tumor , Female , Human Umbilical Vein Endothelial Cells , Humans , MCF-7 Cells , Mice , NIH 3T3 Cells , Phytotherapy , Rats , Rats, Wistar
11.
Am J Med Sci ; 354(1): 54-63, 2017 07.
Article in English | MEDLINE | ID: mdl-28755734

ABSTRACT

BACKGROUND: Cancer stem cells are a subpopulation of tumor cells that are capable of self-renewal, capable of tumor recurrence and metastasis, and in addition are resistant to current cancer therapies. Epigallocatechin-3-gallate is a type of catechin found in green tea that is known for its powerful chemoprotective ability. Hence, this study aimed to investigate the effect of epigallocatechin-3-gallate on 7, 12 dimethylbenzanthracene-induced tumor metastasis, angiogenesis and cancer stem cells. MATERIALS AND METHODS: For this purpose, 3 groups of virgin femal rats with 7,12 dimethylbenzanthracene-induced mammary cancer were treated using epigallocatechin-3-gallate, paclitaxel or their combination. RESULTS: It was found that epigallocatechin-3-gallate exhibited significant chemopreventive effects and anti-cancer stem cell activity through several pathways, including a significant decrease in the size and number of tumors per rat, significant amelioration of the oxidative stress markers' alterations and significant inhibition of CD44, VEGF, Ki-67 and MMP-2 expression associated with a significantly increased expression of caspase-3. Histopathologically, therapy with epigallocatechin-3-gallate resulted in marked necrosis of the neoplastic cells and the tumor masses were mostly replaced by proliferated fibrous tissue so that histological confirmation of a previous tumor was not possible at that site. However, in the combination therapy the neoplastic cells showed marked vacuolation, haphazard arrangement and extensive nuclear pyknosis accompanied with many apoptotic bodies. Therapy with the sole paclitaxel caused variable degrees of necrosis among the neoplastic cells. Additionally, the combination of epigallocatechin-3-gallate and paclitaxel significantly enhanced the later anticancer efficacy. CONCLUSIONS: Epigallocatechin-3-gallatecould be offered as an unprecedented curative strategy to eradicate cancer.


Subject(s)
Anticarcinogenic Agents/pharmacology , Catechin/analogs & derivatives , Mammary Neoplasms, Experimental/drug therapy , Neoplastic Stem Cells/drug effects , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Carcinogens/pharmacology , Catechin/pharmacology , Female , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/secondary , Rats , Rats, Sprague-Dawley
12.
Biomed Pharmacother ; 90: 295-302, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28364601

ABSTRACT

AIM: 2,6-Diisopropylphenol-oleic acid (2,6P-OLA) is an ester conjugate of oleic acid that has displayed a strong anticancer activity on different types of cancer cell lines (Khan et al., 2012). The present study is focused on the development of a nano-liposome-based approach for the delivery of 2,6P-OLA on 7,12-dimethylbenz(a)anthracene (DMBA) induced cutaneous papilloma in experimental mice. For effective and specific delivery of the conjugate to the tumor site, it was incorporated into escheriosome (EC); an Escherichia coli lipid nanoparticle. MATERIALS AND METHODS: I determined the size, zeta-potential, entrapment and release efficacy of 2,6P-OLA-EC nano-formulation. The consequence of 2,6P-OLA-EC treatment was initially analyzed by regression in tumor volume, inhibition of cutaneous papilloma and survival of treated mice. Its anticancer activity was further examined by histopathology, fluorescence microscopy, flow cytometry and electroblot-immuno assay of apoptotic factors. RESULTS: Distinct disperse circular shaped EC nanoparticles showed slow and sustained release of therapeutic concentration of 2,6P-OLA in the surrounding milieu. 2,6P-OLA-EC significantly reduced tumor volume and inhibited onset of new papilloma. Treatment with nano-formulation revealed induced caspase-9 activity and noteworthy apoptotic response as visualized by fluorescence microscopy and TUNEL assay. Electroblot-immuno analysis revealed significant modulation of p53wt and p53mut expression levels. CONCLUSION: The results suggest the therapeutic potential of 2,6P-OLA entrapped in nano-escheriosomes against cutaneous papilloma and can become a promising system against various forms of cancer as well.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene/pharmacology , Apoptosis/drug effects , Carcinogenesis/chemically induced , Carcinogenesis/drug effects , Oleic Acid/pharmacology , Skin Neoplasms/chemically induced , Skin Neoplasms/drug therapy , Animals , Antineoplastic Agents/pharmacology , Liposomes/pharmacology , Male , Mice , Models, Animal , Nanoparticles/chemistry , Papilloma/chemically induced , Papilloma/drug therapy
13.
Mol Pharm ; 14(3): 928-939, 2017 03 06.
Article in English | MEDLINE | ID: mdl-28169546

ABSTRACT

Cancer is a global health problem and chemoprevention is a promising approach for reducing cancer burden. Inositol hexaphosphate (IP6), a natural bioactive constituent of cereals, legumes, etc., has momentous potential as an antiangiogenic agent, that specifically affects malignant cells. The shortcoming is its quick absorption on oral/topical administration. Niosomes are flexible carriers for topical drug delivery. The central venture of current research was to optimize and characterize niosomal delivery system of IP6 for treatment of skin cancer. Thin film hydration method was utilized to prepare IP6 niosomes, and these were dispersed as a suspension in a suitable base. Developed formulations were analyzed for various physicochemical and pharmacological parameters such as particle size, encapsulation efficiency, morphology, drug release, texture analysis, irritability, cell line studies, Western blotting, RT-PCR, and histopathology. IP6 niosomal suspension and IP6 in acetone displayed IC50 value at the concentration of 0.96 mM (0.63 mg/mL) and 1.39 mM (0.92 mg/mL), respectively. IP6 niosomal suspension showed significantly higher (p < 0.05) activity and showed cytotoxic effect in SK-MEL-2 cancer cell line. Crucial events of cellular proliferation and differentiation, like expression of ornithine decarboxylase (ODC), proliferating cell nuclear antigen (PCNA), cycloxygenase-2 (COX-2) and Cyclin D1 were initiated from the fourth hour through application of 7,12-dimethylbenzanthracene (DMBA) on albino mice. The DMBA altered expression of aforesaid enzymes was significantly (P < 0.001) prevented by concomitant application of niosomal formulations. Results of cell line study, Western blotting, RT-PCR, and histopathology suggested that IP6 niosomal suspension could constitute a promising approach for prevention of cellular proliferation as well as DMBA induced dysregulation of cellular proliferation/differentiation and inflammation.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene/pharmacology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Epidermis/drug effects , Inflammation/drug therapy , Phytic Acid/pharmacology , Animals , Chemistry, Pharmaceutical/methods , Cyclin D1/metabolism , Cyclooxygenase 2/metabolism , Disease Models, Animal , Epidermis/metabolism , Female , Mice , Proliferating Cell Nuclear Antigen/metabolism , Tumor Cells, Cultured
14.
J Invest Dermatol ; 137(6): 1322-1332, 2017 06.
Article in English | MEDLINE | ID: mdl-28131816

ABSTRACT

TRAF1 is a member of the TRAF protein family, which regulates the canonical and noncanonical NF-κB signaling cascades. Although aberrant TRAF1 expression in tumors has been reported, the role of TRAF1 remains elusive. Here, we report that TRAF1 is required for solar UV-induced skin carcinogenesis. Immunohistochemical analysis showed that TRAF1 expression is up-regulated in human actinic keratosis and squamous cell carcinoma. In vivo studies indicated that TRAF1 expression levels in mouse skin are induced by short-term solar UV irradiation, and a long-term skin carcinogenesis study showed that deletion of TRAF1 in mice results in a significant inhibition of skin tumor formation. Moreover, we show that TRAF1 is required for solar UV-induced extracellular signal-regulated kinase-5 (ERK5) phosphorylation and the expression of AP-1 family members (c-Fos/c-Jun). Mechanistic studies showed that TRAF1 expression enhances the ubiquitination of ERK5 on lysine 184, which is necessary for its kinase activity and AP-1 activation. Overall, our results suggest that TRAF1 mediates ERK5 activity by regulating the upstream effectors of ERK5 and also by modulating its ubiquitination status. Targeting TRAF1 function might lead to strategies for preventing and treating skin cancer.


Subject(s)
Carcinogenesis/radiation effects , Gene Expression Regulation , Keratinocytes/radiation effects , TNF Receptor-Associated Factor 1/genetics , Ultraviolet Rays/adverse effects , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Analysis of Variance , Animals , Carcinogenesis/drug effects , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Disease Models, Animal , Epidermal Cells , Epidermis/pathology , Gas Chromatography-Mass Spectrometry/methods , Keratinocytes/cytology , Keratinocytes/pathology , Keratosis, Actinic/etiology , Keratosis, Actinic/pathology , Male , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinase 7/metabolism , Mitogen-Activated Protein Kinase 7/radiation effects , Random Allocation , Signal Transduction , Skin Neoplasms/etiology , Skin Neoplasms/physiopathology , Up-Regulation
15.
J Invest Dermatol ; 137(4): 921-930, 2017 04.
Article in English | MEDLINE | ID: mdl-27931797

ABSTRACT

Although the epidermal growth factor receptor has established roles in skin carcinogenesis, inflammation, and wound healing, the functions of the structurally related receptor ERBB2 in this tissue remain poorly explored. To assess the functions of ERBB2 in skin homeostasis, tumorigenesis, and wound healing, we employed keratin 5-directed, cre recombinase-mediated targeting of Erbb2 alleles in mice. Erbb2del mice, lacking ERBB2 specifically in keratinocytes, showed no noticeable spontaneous skin abnormalities. During early wound healing, the thickness and the number and proliferation rate of keratinocytes in the wound epithelium of Erbb2del mice were significantly reduced. Compared with control littermates, Erbb2del mice remained free of papillomas for a longer time and had significantly reduced tumor burden after application of the 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate multistage chemical carcinogenesis protocol. Furthermore, tumor cell proliferation was substantially reduced in Erbb2del mice, and loss of ERBB2 also decreased keratinocyte proliferation after 12-O-tetradecanoylphorbol-13-acetate application. Thus, ERBB2 is dispensable for the development and homeostasis of the epidermis and its appendages. However, reflecting its pro-proliferative role, ERBB2 is required for the normal healing of skin wounds and for the progression of tumors during skin chemical carcinogenesis in mice. Thus, ERBB2 may be a promising target for inhibiting human nonmelanoma skin cancer progression.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene/toxicity , ErbB Receptors/metabolism , Skin Neoplasms/pathology , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Biopsy, Needle , Carcinogenesis/genetics , Cell Proliferation/genetics , Disease Models, Animal , Female , Humans , Immunohistochemistry , Mice , Mice, Inbred C57BL , Random Allocation , Receptor, ErbB-2/metabolism , Reference Values , Skin Neoplasms/chemically induced , Skin Neoplasms/genetics , Statistics, Nonparametric
16.
Lab Anim ; 51(1): 24-35, 2017 Feb.
Article in English | MEDLINE | ID: mdl-26946120

ABSTRACT

Previous studies have established that 7,12-dimethylbenz(a)anthracene (DMBA) can initiate skin tumourigenesis in conventional furred mouse models by acting on hair follicle stem cells. However, further cancer progression depends on repeated applications of tumour promoter agents. This study evaluated the timeline involved in skin tumourigenesis and progression in immunocompetent hairless SKH1-hr mice with dysfunctional hair follicles using only DMBA with no additional tumour promoter agents. The results showed that topical application of 30 µg (117 nmol) of DMBA over the back and flank regions of the mouse once a week and 15 µg (58.5 nmol) twice a week produced skin tumours after 7-8 weeks. However, by week 14 a heavy benign tumour load required the mice to be euthanized. Lowering the DMBA dose to 15 µg (58.5 nmol) once a week produced tumours more slowly and allowed the mice to be studied for a longer period to week 23. This low-dose DMBA regimen yielded a high percentage of malignant tumours (58.8%) after 23 weekly applications. Additionally DMBA-treated skin showed an increase in mean epidermal thickness in comparison to untreated and acetone-treated skin. Despite the aberrant hair follicles in SKH1-hr mice, this chemically driven skin cancer model in hairless mice can serve as a suitable alternative to the ultraviolet-induced skin cancer models and can be reliably replicated as demonstrated by both the pilot and main experiments.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene/pharmacology , Carcinogenesis/chemically induced , Disease Progression , Mice , Skin Neoplasms/chemically induced , 9,10-Dimethyl-1,2-benzanthracene/administration & dosage , Administration, Topical , Animals , Carcinogens/administration & dosage , Carcinogens/pharmacology , Disease Models, Animal , Female , Mice, Hairless
17.
Toxins (Basel) ; 8(11)2016 11 04.
Article in English | MEDLINE | ID: mdl-27827907

ABSTRACT

Pueraria mirifica (PM), a plant whose dried and powdered tuberous roots are now widely used in rejuvenating preparations to promote youthfulness in both men and women, may have major estrogenic influence. In this study, we investigated modifying effects of PM at various doses on mammary and endometrial carcinogenesis in female Donryu rats. Firstly, PM administered to ovariectomized animals at doses of 0.03%, 0.3%, and 3% in a phytoestrogen-low diet for 2 weeks caused significant increase in uterus weight. Secondly, a 4 week PM application to non-operated rats at a dose of 3% after 7,12-dimethylbenz[a]anthracene (DMBA) initiation resulted in significant elevation of cell proliferation in the mammary glands. In a third experiment, postpubertal administration of 0.3% (200 mg/kg body weight (b.w.)/day) PM to 5-week-old non-operated animals for 36 weeks following initiation of mammary and endometrial carcinogenesis with DMBA and N-ethyl-N'-nitro-N-nitrosoguanidine (ENNG), respectively, resulted in significant increase of mammary adenocarcinoma incidence. A significant increase of endometrial atypical hyperplasia multiplicity was also observed. Furthermore, PM at doses of 0.3%, and more pronouncedly, at 1% induced dilatation, hemorrhage and inflammation of the uterine wall. In conclusion, postpubertal long-term PM administration to Donryu rats exerts estrogenic effects in the mammary gland and uterus, and at a dose of 200 mg/kg b.w./day was found to promote mammary carcinogenesis initiated by DMBA.


Subject(s)
Carcinogens/pharmacology , Estrogens/pharmacology , Mammary Glands, Animal/drug effects , Phytoestrogens/pharmacology , Plant Preparations/pharmacology , Pueraria , Uterus/drug effects , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Female , Mammary Glands, Animal/pathology , Mammary Neoplasms, Animal/chemically induced , Mammary Neoplasms, Animal/pathology , Methylnitronitrosoguanidine/analogs & derivatives , Methylnitronitrosoguanidine/pharmacology , Rats , Uterus/pathology
18.
Asian Pac J Cancer Prev ; 17(7): 3527-31, 2016.
Article in English | MEDLINE | ID: mdl-27510004

ABSTRACT

Recombinant human bone morphogenetic protein2 (rhBMP2 ), a member of the TGF? family, has been used widely in recent years to regenerate defects of the maxillary and mandible bones. Such defects are sometimes caused by resection of oral squamous cell carcinoma (OSCC) yet the biologic effects of rhBMP2 on these carcinomas are not fully clear. The objective of this study was to determine histologically whether rhBMP2 produces adverse effects on angiogenesis during induction of OSCC, a biologic process critical for tumor formation in an experimental model in the buccal pouch of golden Syrian hamsters. Buccal cavities were exposed to painting with 0.5% DMBA in liquid paraffin three times a week for 14 weeks, then biopsies were taken. Division was into 2 groups: a study group of 10 hamsters receiving 0.25?g/ml of rhBMP2 in the 3rd and 6th weeks; and a control group of 10 hamsters which did not receive any additional treatment. VEGF expression and microvessel density were measured but no differences were noted between the two groups. According to this study, rhBMP2 does not stimulate angiogenesis during induction of OCSSs.


Subject(s)
Bone Morphogenetic Protein 2/metabolism , Carcinoma, Squamous Cell/metabolism , Mouth Neoplasms/metabolism , Neovascularization, Pathologic/metabolism , Recombinant Proteins/metabolism , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Carcinoma, Squamous Cell/chemically induced , Cheek , Cricetinae , Humans , Male , Mesocricetus , Microvessels/metabolism , Morphogenesis/physiology , Mouth Neoplasms/chemically induced , Transforming Growth Factor beta/metabolism , Vascular Endothelial Growth Factor A/metabolism
19.
Int J Med Sci ; 13(7): 533-9, 2016.
Article in English | MEDLINE | ID: mdl-27429590

ABSTRACT

OBJECTIVE: Oral squamous cell carcinoma (OSCC) is the most common malignancy of head and neck with high mortality rates. The mechanisms of initiation and development of OSCC remain largely unknown. Dysregulated alternative splicing of pre-mRNA has been associated with OSCC. Splicing factor SRSF3 is a proto-oncogene and overexpressed in multiple cancers. The aim of this study was to uncover the relationship between SRSF3 and carcinogenesis and progression of oral squamous cell carcinoma. DESIGN AND METHODS: The expression of SRSF3 in oral normal, dysplasia, or carcinoma tissues was analyzed by immunohistochemistry. The expression levels of EMT-related genes were quantified by real-time quantitative RT-PCR. The expression of SRSF3 in DMBA treated primary cultured oral epithelial cells were analyzed by western blot. RESULT: SRSF3 is overexpressed in oral cancer and moderate or severe dysplasia tissues. Patients with high grade cancer or lymphatic metastasis showed up-regulated expression of SRSF3. Knockdown of SRSF3 repressed the expression of Snail and N-cadherin in vitro. Carcinogen DMBA treated primary cultured oral epithelial cells showed significantly increased SRSF3 level than in control cells. CONCLUSION: Our results suggested that SRSF3 is associated with the initiation and development of OSCC and may be a biomarker and therapeutic target of OSCC.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Mouth Neoplasms/metabolism , Mouth Neoplasms/pathology , Serine-Arginine Splicing Factors/metabolism , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Blotting, Western , Carcinogenesis/metabolism , Carcinogenesis/pathology , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Epithelial-Mesenchymal Transition/physiology , Female , Gene Expression Regulation, Neoplastic/physiology , Gingiva/cytology , Humans , Immunohistochemistry , In Vitro Techniques , Male , Middle Aged , Proto-Oncogene Mas , Reverse Transcriptase Polymerase Chain Reaction
20.
Eur Rev Med Pharmacol Sci ; 20(13): 2935-46, 2016 07.
Article in English | MEDLINE | ID: mdl-27424997

ABSTRACT

OBJECTIVE: Resveratrol (RES), present in fruits and plants, is a natural compound that has been shown various medicinal properties, including protection of cardiovascular disease and cancer risk. However, the effects of RES on skin cancer have not been investigated. The present work was designed to explore the anticancer potential of RES against chemical-induced skin carcinogenesis in rats. MATERIALS AND METHODS: Skin carcinogenesis were induced in male Wistar rats by a single topical application of 7,12-dimethylbenz(a)anthracene (DMBA) and 2 weeks later, 12-O-tetradecanoylphorbol-13-acetate (TPA) were topically applied thrice a week to promote skin carcinogenesis. RES at a dose of 1 or 2 mg/kg body weight/week were administered to DMBA treated rats. The effects of RES on DMBA-modified cell-cycle arrest, apoptosis and protein expressions were analyzed by flow cytometry, immunohistochemistry and Western blot, respectively. RESULTS: RES treatment caused a significant reduction of DMBA-induced tumor occurrence, tumor volume and tumor weight, as compared to DMBA control group. Further, RES treatment increases G2/M arrest and apoptosis by modulating cell-cycle and apoptosis regulated genes such as p53, p21, caspase-3, bax, survivin, cyclin-B and cdc-2 when compared with DMBA control group. CONCLUSIONS: Taken together, the anticancer effect of RES is associated with regulation of cell-cycle and apoptosis in skin cancer, thereby attenuating skin cancer growth. Hence, these findings suggest that RES may be a therapeutic agent for skin cancer treatment.


Subject(s)
Anticarcinogenic Agents/pharmacology , Apoptosis/drug effects , Cell Cycle Checkpoints/drug effects , Stilbenes/pharmacology , 9,10-Dimethyl-1,2-benzanthracene/pharmacology , Animals , Carcinogenesis/drug effects , Male , Rats , Rats, Wistar , Resveratrol , Skin Neoplasms/prevention & control , Tetradecanoylphorbol Acetate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...